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Abst rac t
Background and purpose: Sporadic amyotrophic lateral
sclerosis (sALS) is a devastating neurodegenerative disease,
which results from complex genetic and environmental
interactions. Recent studies have reported an association
between several polymorphisms of the PON1 and PON2
genes and risk of sALS. The aim of the present study was to
identify an association between the –A162G polymorphism
of the promoter region of the human PON1 gene and the risk
of sALS in a Polish population.
Material and methods: We included 259 patients with
a diagnosis of definite or probable sALS (76 bulbar onset,
183 limb onset) and 694 healthy controls matched for age
and sex. The diagnosis of ALS was established according to
El Escorial criteria. The polymorphism was studied by Single
Nucleotide Polymorphism Real-Time Polymerase Chain
Reaction analysis.
Results: No overall difference in the PON1 –A162G geno -
type and allele distribution was seen between cases and
controls (all p > 0.05). There was, however, a difference in
the A allele frequency when the bulbar onset group was
compared to the controls (p = 0.03), but this significance
disappeared after the Bonferroni correction.
Conclusions: The results did not show that the –A162G
polymorphism of the PON1 gene is a risk factor of sALS in
a Polish population; it may affect, however, bulbar onset of
the disease.
Key words: amyotrophic lateral sclerosis, PON1, poly -
morphism.
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St reszczenie
Wstêp i cel pracy: Sporadyczna postaæ stwardnienia bocznego
zanikowego (sSLA) jest chorob¹ zwyrodnieniow¹ uk³adu ner-
wowego, w której etiopatogenezie kluczow¹ rolê odgrywaj¹ 
inter akcje miêdzy czynnikami genetycznymi i œrodowiskowymi.
Dotychczasowe badania wskazuj¹ na istnienie zale¿noœci miêdzy
polimorfizmami genów PON1 i PON2 a ryzykiem wyst¹pienia
sSLA. Celem pracy by³o zbadanie, czy istnieje zwi¹zek miêdzy
polimorfizmem –A162G miejsca promotorowego genu PON1
a ryzykiem wyst¹pienia sSLA w populacji polskiej.
Materia³ i metody: Badanie przeprowadzono u 259 chorych, u któ-
rych zgodnie z kryteriami El Escorial rozpoznano pewne lub praw-
dopodobne SLA (76 osób z postaci¹ opuszkow¹, 183 osoby z posta-
ci¹ koñczynow¹) oraz u 694 zdrowych ochotników, stanowi¹cych
grupê kontroln¹ dobran¹ pod wzglêdem wieku i p³ci. Polimorfizm
genu PON1 by³ badany za pomoc¹ reakcji ³añcuchowej polimera-
zy DNA z analiz¹ iloœci produktu w czasie rzeczywistym.
Wyniki: Nie stwierdzono istotnych statystycznie ró¿nic
w rozk³adzie genotypów i alleli genu PON1 miêdzy grup¹ cho-
rych a grup¹ kontroln¹ (p > 0,05). Stwierdzono natomiast
ró¿nice w czêstoœci wystêpowania allela A miêdzy grup¹ cho-
rych z postaci¹ opuszkow¹ w porównaniu z grup¹ kontroln¹ 
(p = 0,03), jednak po korekcie Bonferroniego wynik ten nie by³
ju¿ istotny statystycznie.
Wnioski: Wyniki naszego badania nie wykaza³y, aby poli-
morfizm –A162G genu PON1 by³ czynnikiem ryzyka sSLA
w populacji polskiej, jednak sugeruj¹, ¿e mo¿e mieæ znacze-
nie dla wyst¹pienia postaci opuszkowej tej choroby. 
S³owa kluczowe: stwardnienie boczne zanikowe, PON1, poli-
morfizm. 
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Introduction
Sporadic amyotrophic lateral sclerosis (sALS) is
a complex motor neuron disorder whose pathogenesis
is still unknown. An interaction of genetic variants and
environmental exposure is proposed to be an important
cause of the disease [1-4]. 
Paraoxonases (PONs) PON1, PON2 and PON3
are esterase enzymes that possess antioxidative proper-
ties [5]. PON1 is also able to break down organophos-
phate insecticides, pesticides and nerve gases [5]. The
PON gene cluster is located on chromosome 7 (7q21.3–
22.1) [5]. The PON1 gene has several common poly-
morphisms: some of them alter enzyme activity and
some affect its expression [6]. The functional –A162G
(rs705381) polymorphism is located in the promoter
region of the human PON1 gene [7-9]. Experimental
studies on transient transfection human hepatoma cell
line revealed that the –162A allele, as part of haplotypes,
conferred 1.8 to 3.6-fold higher reporter expression 
levels of the gene than the G allele [8]. In a human
study the A allele was associated with increased plasma
activity of the enzyme [7].
Recently, the association between different PON
gene variants and sALS was shown in many different
populations [3,6,10-14], with only one exception [15].
A recent meta-analysis including all published studies
demonstrated that among several different polymor-
phisms the Q192R variant of the PON1 gene was a risk
factor of sALS (OR = 1.25, 95% CI: 1.07–1.45, 
p = 0.004), although after a Bonferroni correction these
results were not significant [16].
The association between the –A162G polymorphism
of the PON1 gene and the risk of sALS was studied in
patients from Ireland, France, Quebec and Sweden and
yielded negative results [6,11]. To date, an association
between the –A162G polymorphism of the PON1 gene
and the risk of sALS has been found only in an Aus-
tralian population [14].
The aim of the present study was to identify any asso-
ciation between the –A162G polymorphism of the PON1
gene and the risk of sALS in the Polish population.
Material and methods
Subjects
We included 259 consecutive patients with sALS
selected among patients of the MND outpatient clinic,
Department of Neurology, Jagiellonian University,
Krakow between 2003 and 2009. All patients fulfilled
the El Escorial criteria for clinically definite or proba-
ble ALS [17]. Familial ALS cases were excluded based
on a positive family history of the disease.
The following information about patients was col-
lected: age, gender, type of disease onset (bulbar or
limb), and type of clinical ALS diagnosis.
The control group included 694 unrelated individ-
uals selected from the population of Southern Poland.
Control subjects had no apparent neurological disease
based on the findings of a structured questionnaire and
neurological examination. Controls were matched to
patients with respect to age of patients at disease onset
(±5 years) and gender. 
Both cases and controls were of Caucasian origin and
Polish descent. The local Ethical Committee approved
the study protocol. All individuals gave written informed
consent prior to inclusion in the study.
Methods
Genetic analyses were performed by laboratory per-
sonnel who were kept blind to sample identity. Leuko-
cyte DNA was extracted using a commercially available
kit (Boehringer Mannheim, Germany).
Genotyping was performed on an ABI PRISM®
7900HT Fast Real-Time PCR System (Applied Biosys-
tems) using TaqMan Universal PCR Master Mix
(Applied Biosystems). Amplifications were carried out
using a Standard Curve (AQ) plate document to gen-
erate real-time PCR data and fluorescence was read
using an Allelic Discrimination (AD) plate document.
The thermal cycling protocol was: 95°C for 10 min, fol-
lowed by 40 cycles of 95°C for 15 s and 60°C for 1 min.
For each sample in the AD assay, a unique pair of Taq-
Man® MGB probes was used. One fluorescent dye
detector (VIC) was a perfect match to the wild type allele
and the other (FAM) to the mutant allele. SDS soft-
ware (Applied Biosystems) was used to plot and auto-
matically call genotypes based on a two parameter plot
using fluorescence intensities of FAM and VIC.
Assays were ordered from Applied Biosystems 
as Pre-Designed/Validated Assays for PON1 (paraoxo -
nase 1), rs705381. 
Statistical analysis
Wilcoxon test was used to check the potential dif-
ference in age at disease onset, and a χ2 test was used to
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check the potential difference in gender distribution
between the studied groups. Allele frequencies were cal-
culated by allele counting. Deviations of the observed
genotypes were identified by χ2 test from Hardy-Wein-
berg equilibrium. Association of the –A162G PON1
polymorphism with sALS was studied with χ2 test at the
level of genotypes and alleles; when the number of sub-
jects in each group was lower than five, the Fisher exact
test was used. Genetic association tests were performed
in PLINK, including subsidiary analysis of dominant,
recessive, genotypic, and Cochran-Armitage trend tests.
Results were adjusted for multiple testing using the Bon-
ferroni correction. After the correction a value of 
p < 0.012 was considered significant. Calculations were
performed using the statistical package SAS v.9.1 and
PLINK v.1.06.
Results
Patients and controls presented with similar age and
gender distribution (ALS group: 52.12% males, mean
age: 56.2 ±12.7 years, control group: 54.47% males,
mean age: 55.6 ±17.2 years). Thirty percent of cases
(76 patients) presented with bulbar onset.
Genotype frequencies were in Hardy-Weinberg equi-
librium for the entire group as well as for patients and
controls separately (p > 0.05). 
Genotype and allele frequencies did not differ
between patients and controls (Table 1). 
There was no difference in the genotype and allele
distribution when patients with limb onset were com-
pared with the controls (Table 2). The frequency of the
A allele was significantly lower in patients with bulbar
onset when compared with the controls (p = 0.03). This
significance, however, disappeared after the Bonferroni
correction (Table 3).
Discussion
The present study did not show any difference in the
PON1 –A162G genotype and allele distribution between
patients with sALS and controls; however, patients with
bulbar onset of the disease, as opposed to patients with
limb onset, presented with lower frequency of the A allele
as compared with the controls. Because we performed
multiple comparisons, we used a Bonferroni correction
to avoid a type 1 error. This resulted in decreasing the
expected p-value to less than 0.012. Our results, after the
Bonferroni correction, were no longer significant. 
Although finally we were not able to show a signifi-
cant difference in the genotype and allele distribution
between the bulbar onset sALS and the controls, we can-
not exclude that such a difference exists. Including more
patients and controls or performing a meta-analysis on
existing data may answer this question. The two types of
ALS distinguished at disease onset are thought to pre-
sent with similar pathophysiology; however, several data
highlight some differences in the clinical picture and risk
factor profile [18]. Bulbar onset is more common in
women and in older patients and is characterized by
a shorter survival time [2,18]. Recently Chiò et al. [19]
showed that a longer lasting career of a professional soc-
sALS Control group p-value OR (95% CI)
(n = 259) (n = 694)
Genotypes
GG 143 (55.2%) 394 (56.8%) 0.67* 0.94 (0.70-1.25)*
GA 101 (39.0%) 259 (37.3%) 0.95** 0.98 (0.53-1.08)**
AA 15 (5.8%) 41 (5.9%)
0.74***
Alleles
G 387 (74.7%) 1047 (75.4%) 0.75‡ 0.96 (0.76-1.21)‡
A 131 (25.3%) 341 (24.6%)
Table 1. Distribution of genotypes and alleles of the PON1 gene –A162G polymorphism in sALS patients as compared to controls
* Statistical calculation based on the comparison of AA + GA vs. GG genotypes (χ2 test).
** Statistical calculation based on the comparison of GG + GA vs. AA genotypes (χ2 test).
*** The Cochran-Armitage test for trend.
‡Statistical calculation based on the comparison of G vs. A allele (χ2 test).
sALS – sporadic amyotrophic lateral sclerosis, OR – odds ratio, CI – confidence interval
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cer player resulted in higher risk of bulbar onset sALS.
Differences in genetic risk factor profile were also noted
[20,21]. Al Chalabi et al. [21] showed a significantly
higher proportion of bulbar onset ALS in carriers of at
least one epsilon4 allele of the APOE gene compared to
limb onset ALS and to the controls. Also a recently pub-
lished genome-wide association study (GWAS) in sALS
showed different genetic profile in the two types of sALS
[22]. The bulbar onset sALS as compared with the con-
trols was characterized by different distribution of some
genetic variants in the following genes: AMPH,
BU173572, PARP8, PCSK5 [22]. 
The –A162G polymorphism of the PON1 gene
seems to be a good candidate for a genetic risk factor of
ALS. This polymorphism is located within a potential
binding site of the transcription factor NF-I (nuclear
factor I), which may implicate a transcriptional process
of the PON1 gene [8]. The studies of Brophy et al.
[7,8] revealed that the –162A phenotype is related to
increased activity of PON1, which means that this phe-
notype has the greatest hydrolytic activity against
organophosphate chemicals and is more effective in pro-
tecting LDL against oxidation. There are some indica-
tions that increased exposure to organophosphate chem-
sALS – limb onset Control group p-value OR (95% CI)
(n = 183) (n = 694)
Genotypes
GG 94 (51.4%) 394 (56.8%) 0.19*
GA 74 (40.4%) 259 (37.3%) 0.26** 0.81 (0.59-1.12)*
AA 15 (8.2%) 41 (5.9%)
0.13*** 0.75 (0.40-1.41)**
Alleles
G 262 (71.6%) 1047 (75.4%)
0.13‡ 0.82 (0.63-1.06)‡
A 104 (28.4%) 341 (24.6%)
Table 2. Distribution of genotypes of the PON1 gene –A162G polymorphism in limb onset sALS patients as compared to controls
* Statistical calculation based on the comparison of AA + GA vs. GG genotypes (χ2 test).
** Statistical calculation based on the comparison of GG + GA vs. AA genotypes (χ2 test).
*** The Cochran-Armitage test for trend.
‡ Statistical calculation based on the comparison of G vs. A allele (χ2 test).
sALS – sporadic amyotrophic lateral sclerosis, OR – odds ratio, CI – confidence interval
sALS – bulbar onset Control group p-value OR (95% CI)
(n = 76) (n = 694)
Genotypes
GG 49 (64.5%) 394 (56.8%) 0.22*
GA 27 (35.5%) 259 (37.3%) 0.03** 1.38 (0.84-2.26)*
AA 0 (0.0%) 41 (5.9%)
0.06*** unavailable**
Alleles
G 125 (82.2%) 1047 (75.4%)
0.07‡ 1.51 (0.98-2.33)‡
A 27 (17.8%) 341 (24.6%)
Table 3. Distribution of genotypes of the PON1 gene –A162G polymorphism in bulbar onset sALS patients as compared to controls
*Statistical calculation based on the comparison of AA + GA vs. GG genotypes (χ2 test).
**Statistical calculation based on the comparison of GG + GA vs. AA genotypes (Fisher exact test).
***The Cochran-Armitage test for trend.
‡Statistical calculation based on the comparison of G vs. A allele (χ2 test).
sALS – sporadic amyotrophic lateral sclerosis, OR – odds ratio, CI – confidence interval
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icals and/or increased lipid oxidation may increase 
the risk of sALS [4,10]. An association between the 
–A162G polymorphism and the risk of sALS was pre-
viously demonstrated by Morahan et al. [14]. They
indicated that the A allele is a protective factor against
this disease. Our results are in line with these data, sug-
gesting that the A allele may protect against bulbar onset
ALS. It is important to note that a study on French,
Canadian and Swedish patients did not show any dif-
ference in the PON1 –A162G genotype and allele dis-
tribution between patients with sALS and controls [11].
Moreover, no correlation was found between the stud-
ied genetic variant and different types of sALS [11].
The possible association with the –A162G poly-
morphism of the PON1 gene was also investigated in
another neurodegenerative disease, i.e. Alzheimer dis-
ease. Erlich et al. [9] found an association between the
–A162G polymorphism of the PON1 gene and
Alzheimer disease. However, in contrast to our results,
the A allele had a deleterious effect on disease risk, both
independently and as part of several haplotypes. This
result was not expected by the authors. Based on their
results, the authors speculated that Alzheimer disease
may be associated with reduced, not elevated, as expect-
ed from experimental data, levels of serum paraoxonase.
Conclusion
The results did not show that the –A162G poly-
morphism of the PON1 gene is risk factor of sALS.
However, it may affect bulbar onset of the disease.
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